Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod versus fingolimod in pediatric relapsing-remitting multiple sclerosis
MOH_2022-12-11_011993Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Nov 2022
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ponesimod and fingolimod in multiple sclerosis (MS) (3 arms), sponsored by Janssen-Cilag. Started Nov 2022; status: completed.
02
Drugs
ponesimodfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2022-12-11_011993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-11_011993.